Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Alb-ZnDDC
- Development stage
- Preclinical
- Lead developer
- University of Wolverhampton
- Modality
- Nanoparticles → Drug Delivery Systems, Small Molecules
01
Overview
Alb-ZnDDC is an albumin-based nanoparticle formulation encapsulating zinc diethyldithiocarbamate (Zn(DDC)₂), developed to enhance the stability and bioavailability of disulfiram-derived metal complexes for cancer therapy. Disulfiram, an anti-alcoholism drug, forms potent anticancer chelates with metal ions like zinc, but its clinical utility is limited by a very short plasma half-life. Alb-ZnDDC addresses these issues by providing a soluble, long-circulating delivery system. In preclinical studies, it has demonstrated significant cytotoxicity against pancreatic ductal adenocarcinoma (PDAC) across various conditions, including hypoxia and spheroid models, and has shown synergistic potential when combined with gemcitabine or paclitaxel. Research into its resistance profile has identified the cysteine protease inhibitor CST1 as a potential mediator of acquired resistance to this agent.
- Other names
- albumin nano-encapsulated zinc diethyldithiocarbamatealbumin-based zinc diethyldithiocarbamate nanoparticlesAlb-Zn(DDC)2
Beyond the preview
Go deeper on Alb-ZnDDC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Alb-ZnDDC.